Exploring Ruthenium-Based Organometallic Inhibitors against Plasmodium falciparum Calcium Dependent Kinase 2 (PfCDPK2): A Combined Ensemble Docking, QM/MM and Molecular Dynamics Study

Recent advances in the metal-organic framework (MOF) have accelerated the discovery of novel metal-based anticancer, antibacterial and antimalarial compounds. This is substantiated by many serendipitously discovered metals (Ru, Rh, and Ir) based inhibitors that established the importance of metal inserted into the known organic scaffold. Conversely, it is possible to design novel bioactive compounds by mimicking hypervalent carbon atoms by transition metals. This process can be facilitated by computational drug discovery by treating metal centres using optimized parameters that can be used for molecular docking and molecular dynamics simulations. Further, the method can be plugged with high computational power and refined algorithms to interpret chemical phenomena with atomic-level insights. In the present work, we have demonstrated an approach for parameterizing three organometallic ligands (FLL, E52, and staurosporine) using MCPB.py. In particular, we report that E52 and FLL have a better shape complimentary and affinity compared to staurosporine identified inhibitor (staurosporine) against Calcium-dependent protein kinases 2 (CDPK2). This study also revealed that a flexible approach (ensemble) outperforms the given target with dynamic movements. The calculated MM-PBSA energies for staurosporine, FLL and E52 were -66.461 +/- 2.192, -67.182 +/- 1.971 and -91.339 +/- 2.745 kJ/mol, respectively.

Automated summary

Recent advancements in metal-organic frameworks have led to the discovery of novel metal-based compounds with anticancer, antibacterial, and antimalarial properties. By mimicking hypervalent carbon atoms with transition metals, it is possible to design bioactive compounds with optimized parameters for molecular docking and dynamics simulations. Computational drug discovery and parameterization of organometallic ligands show promising potential for developing new treatments for diseases like cancer.